AU Patent

AU2016340087C1 — Combination therapy for treating malignancies

Assigned to Les Laboratoires Servier SAS · Expires 2022-08-18 · 4y expired

What this patent protects

Provided are methods and compositions for treating AML in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and an AML induction and consolidation therapy.

USPTO Abstract

Provided are methods and compositions for treating AML in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and an AML induction and consolidation therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016340087C1
Jurisdiction
AU
Classification
—
Expires
2022-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Les Laboratoires Servier SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.